Researchers from the Shanghai Institute of Nutrition and Health and Guangming Advanced Research Institute described a circular RNA (circRNA) encoding human relaxin‑2 (cRLN2) as a protein‑replacement strategy to treat liver fibrosis. The team emphasized circRNA stability and low immunogenicity as advantages for sustained protein expression in hepatic tissue. Preclinical data presented by the authors show therapeutic activity in models of liver fibrosis, supporting circRNA as an alternative modality for chronic protein delivery. The study positions circRNA therapeutics alongside mRNA and viral vectors as a potential route for durable cytokine or growth‑factor replacement with favorable pharmacology. Translational teams will assess manufacturability, tissue targeting, dosing durability and immune readouts as circRNA moves toward clinical translation in fibrotic and other chronic diseases.